Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans

American Journal of Ophthalmology

Volumn 154, Issue 4, 2012, Pages 682-686.e2

  Krohne, Tim U ^a   Liu, Zengping ^a   Holz, Frank G ^a   Meyer, Carsten H ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ADULT; AGED; AQUEOUS HUMOR; ARTICLE; CATARACT; CATARACT EXTRACTION; CLINICAL ARTICLE; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE AXIS LENGTH; FEMALE; HUMAN; INTERVENTION STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONLINEAR REGRESSION ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; RETINA MACULOPATHY; RETINA VEIN OCCLUSION; SINGLE DRUG DOSE;

EID: 84866398752     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2012.03.047     Document Type: Article

References (26)

1. P.J. Rosenfeld, D.M. Brown, J.S. Heier Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 14 2006 1419 1431 (Pubitemid 44511557)
2. D.M. Brown, P.K. Kaiser, M. Michels Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 14 2006 1432 1444 (Pubitemid 44511558)
3. P. Mitchell, F. Bandello, U. Schmidt-Erfurth The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema Ophthalmology 118 4 2011 615 625
4. D.M. Brown, P.A. Campochiaro, R.P. Singh Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study Ophthalmology 117 6 2010 1124 1133.e1121
5. P.A. Campochiaro, J.S. Heier, L. Feiner Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study Ophthalmology 117 6 2010 1102 1112.e1101
6. T.U. Krohne, N. Eter, F.G. Holz, C.H. Meyer Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans Am J Ophthalmol 146 4 2008 508 512
7. K.D. Teichmann Intravitreal injections: does globe size matter? J Cataract Refract Surg 28 10 2002 1886 1889 (Pubitemid 35204655)
8. C.H. Meyer, T.U. Krohne, F.G. Holz Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans Retina 31 9 2011 1877 1884
9. M.W. Stewart Predicted biologic activity of intravitreal bevacizumab Retina 27 9 2007 1196 1200 (Pubitemid 350211524)
10. M.W. Stewart, P.J. Rosenfeld, F.M. Penha Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye) Retina 32 3 2012 434 457
11. M.W. Stewart, P.J. Rosenfeld Predicted biological activity of intravitreal VEGF Trap Br J Ophthalmol 92 5 2008 667 668 (Pubitemid 351684178)
12. S.J. Bakri, M.R. Snyder, J.M. Reid, J.S. Pulido, R.J. Singh Pharmacokinetics of intravitreal bevacizumab (Avastin) Ophthalmology 114 5 2007 855 859 (Pubitemid 46635858)
13. T. Miyake, O. Sawada, M. Kakinoki Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes Invest Ophthalmol Vis Sci 51 3 2010 1606 1608
14. H.S. Chin, T.S. Park, Y.S. Moon, J.H. Oh Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes Retina 25 5 2005 556 560
15. P.M. Beer, S.J. Bakri, R.J. Singh, W. Liu, G.B. Peters 3rd, M. Miller Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection Ophthalmology 110 4 2003 681 686 (Pubitemid 36520063)
16. S.J. Bakri, M.R. Snyder, J.M. Reid, J.S. Pulido, M.K. Ezzat, R.J. Singh Pharmacokinetics of intravitreal ranibizumab (Lucentis) Ophthalmology 114 12 2007 2179 2182 (Pubitemid 350181137)
17. J. Gaudreault, D. Fei, J. Rusit, P. Suboc, V. Shiu Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration Invest Ophthalmol Vis Sci 46 2 2005 726 733 (Pubitemid 40270359)
18. J. Gaudreault, D. Fei, J.C. Beyer Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits Retina 27 9 2007 1260 1266 (Pubitemid 350211535)
19. H. Nomoto, F. Shiraga, N. Kuno Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits Invest Ophthalmol Vis Sci 50 10 2009 4807 4813
20. J. Mordenti, R.A. Cuthbertson, N. Ferrara Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration Toxicol Pathol 27 5 1999 536 544 (Pubitemid 29446822)
21. European Medicines Agency (EMA) Lucentis: Scientific Discussion (March 14, 2007) http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific- Discussion/human/000715/WC500043550.pdf Accessed: March 28, 2012
22. H. Kim, R.N. Fariss, C. Zhang, S.B. Robinson, M. Thill, K.G. Csaky Mapping of the neonatal Fc receptor in the rodent eye Invest Ophthalmol Vis Sci 49 5 2008 2025 2029
23. H. Kim, S.B. Robinson, K.G. Csaky FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye Mol Vis 15 2009 2803 2812
24. D.C. Roopenian, S. Akilesh FcRn: the neonatal Fc receptor comes of age Nat Rev Immunol 7 9 2007 715 725 (Pubitemid 47327396)
25. N. Ferrara, L. Damico, N. Shams, H. Lowman, R. Kim Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration Retina 26 8 2006 859 870 (Pubitemid 44547437)
26. D.F. Martin, M.G. Maguire, G.S. Ying, J.E. Grunwald, S.L. Fine, G.J. Jaffe Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 20 2011 1897 1908